Search hospitals > Ontario > HAMILTON
McMaster University
Claim this profileHAMILTON, Ontario L8N 3Z5
Global Leader in Allergy and Asthma
Global Leader in Asthma
Conducts research for Stroke
Conducts research for Crohn's Disease
Conducts research for Colitis
258 reported clinical trials
42 medical researchers
Summary
McMaster University is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Allergy and Asthma, Asthma, Stroke, Crohn's Disease, Colitis and other specialties. McMaster University is involved with conducting 258 clinical trials across 685 conditions. There are 42 research doctors associated with this hospital, such as Jeff S Healey, MD, Moin Khan, MD, Ryan Van Lieshout, MD, PhD, and Shamir Mehta, MD.Top PIs
Jeff S Healey, MDHamilton Health Sciences Centre1 year of reported clinical research
Studies Atrial Fibrillation
Studies Stroke
7 reported clinical trials
11 drugs studied
Moin Khan, MDSt. Joseph's Healthcare Hamilton2 years of reported clinical research
Studies Dislocated Toe(s)
Studies Shoulder Dislocation
7 reported clinical trials
9 drugs studied
Ryan Van Lieshout, MD, PhDMcMaster University5 years of reported clinical research
Studies Pregnancy or Postpartum
Studies Depression Treatment
6 reported clinical trials
5 drugs studied
Shamir Mehta, MDHamilton Health Science Centre5 years of reported clinical research
Studies Tricuspid Regurgitation
Studies Heart Disease
5 reported clinical trials
7 drugs studied
Clinical Trials running at McMaster University
Atrial Fibrillation
Coronary Artery Disease
Depression Treatment
Major Depression
Hemophilia B
Celiac Disease
Osteoarthritis
Inflammatory Bowel Disease
Tourette Syndrome
Postprandial Fullness Syndrome
Vernakalant vs. Procainamide
for Atrial Fibrillation
The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.
Recruiting3 awards Phase 44 criteria
Pericardiotomy
for Cardiovascular Disease
PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.
Recruiting1 award N/A1 criteria
Electrode Positioning
for Atrial Fibrillation Cardioversion
Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year. We believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk. Electrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is "shocked" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial. This study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation. We will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal. We hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.
Recruiting1 award N/A1 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McMaster University?
McMaster University is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Allergy and Asthma, Asthma, Stroke, Crohn's Disease, Colitis and other specialties. McMaster University is involved with conducting 258 clinical trials across 685 conditions. There are 42 research doctors associated with this hospital, such as Jeff S Healey, MD, Moin Khan, MD, Ryan Van Lieshout, MD, PhD, and Shamir Mehta, MD.